X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17811) 17811
Newsletter (47) 47
Magazine Article (37) 37
Book Chapter (16) 16
Newspaper Article (16) 16
Conference Proceeding (4) 4
Publication (2) 2
Transcript (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16672) 16672
antineoplastic combined chemotherapy protocols - therapeutic use (11395) 11395
female (10449) 10449
male (10402) 10402
vincristine - administration & dosage (9481) 9481
science & technology (8277) 8277
life sciences & biomedicine (8154) 8154
vincristine - therapeutic use (7374) 7374
middle aged (7351) 7351
adult (7043) 7043
cyclophosphamide - administration & dosage (6259) 6259
doxorubicin - administration & dosage (5662) 5662
aged (5388) 5388
oncology (4580) 4580
prednisone - administration & dosage (4380) 4380
cyclophosphamide - therapeutic use (4348) 4348
adolescent (3768) 3768
prednisone - therapeutic use (3571) 3571
doxorubicin - therapeutic use (3231) 3231
combined modality therapy (3119) 3119
child (3109) 3109
treatment outcome (2963) 2963
prognosis (2857) 2857
hematology (2704) 2704
chemotherapy (2627) 2627
antineoplastic combined chemotherapy protocols - administration & dosage (2570) 2570
child, preschool (2387) 2387
antineoplastic combined chemotherapy protocols - adverse effects (2288) 2288
abridged index medicus (2229) 2229
methotrexate - administration & dosage (2075) 2075
vincristine - adverse effects (2035) 2035
remission induction (1986) 1986
vincristine (1934) 1934
etoposide - administration & dosage (1829) 1829
drug therapy, combination (1711) 1711
neoplasm staging (1682) 1682
follow-up studies (1656) 1656
lymphoma, large b-cell, diffuse - drug therapy (1640) 1640
lymphoma, non-hodgkin - drug therapy (1636) 1636
antineoplastic agents - therapeutic use (1613) 1613
cancer (1601) 1601
retrospective studies (1580) 1580
bleomycin - administration & dosage (1566) 1566
infant (1566) 1566
methotrexate - therapeutic use (1464) 1464
disease-free survival (1416) 1416
rituximab (1410) 1410
survival rate (1401) 1401
hodgkin disease - drug therapy (1388) 1388
aged, 80 and over (1279) 1279
time factors (1267) 1267
procarbazine - administration & dosage (1239) 1239
cyclophosphamide - adverse effects (1185) 1185
survival analysis (1172) 1172
drug administration schedule (1168) 1168
prednisolone - administration & dosage (1152) 1152
lymphomas (1129) 1129
animals (1115) 1115
doxorubicin - adverse effects (1088) 1088
cisplatin - administration & dosage (1043) 1043
cytarabine - administration & dosage (1009) 1009
prednisone - adverse effects (946) 946
care and treatment (942) 942
pediatrics (917) 917
clinical trials as topic (860) 860
lung neoplasms - drug therapy (848) 848
prospective studies (818) 818
young adult (816) 816
dexamethasone - administration & dosage (807) 807
dactinomycin - administration & dosage (799) 799
lymphoma, large b-cell, diffuse - pathology (768) 768
lymphoma - drug therapy (766) 766
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (766) 766
procarbazine - therapeutic use (765) 765
cyclophosphamide (764) 764
leukemia, lymphoid - drug therapy (731) 731
recurrence (729) 729
neoplasm metastasis (701) 701
antibodies, monoclonal, murine-derived (691) 691
cytarabine - therapeutic use (677) 677
dacarbazine - administration & dosage (666) 666
risk factors (662) 662
remission, spontaneous (656) 656
doxorubicin (642) 642
bleomycin - therapeutic use (641) 641
medicine & public health (633) 633
prednisolone - therapeutic use (630) 630
mechlorethamine - administration & dosage (627) 627
dactinomycin - therapeutic use (625) 625
hodgkin disease - radiotherapy (615) 615
lymphoma, b-cell - drug therapy (611) 611
tomography, x-ray computed (611) 611
multiple myeloma - drug therapy (609) 609
lymphoma (604) 604
radiotherapy (586) 586
etoposide - therapeutic use (581) 581
antibodies, monoclonal, murine-derived - therapeutic use (575) 575
breast neoplasms - drug therapy (566) 566
mice (549) 549
age factors (548) 548
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15177) 15177
Japanese (1024) 1024
German (686) 686
French (441) 441
Chinese (306) 306
Spanish (288) 288
Russian (238) 238
Italian (185) 185
Polish (174) 174
Hungarian (30) 30
Portuguese (26) 26
Dutch (25) 25
Hebrew (17) 17
Danish (15) 15
Czech (12) 12
Serbian (12) 12
Norwegian (7) 7
Romanian (7) 7
Swedish (7) 7
Ukrainian (7) 7
Bulgarian (5) 5
Croatian (5) 5
Finnish (5) 5
Slovak (3) 3
Turkish (3) 3
Korean (2) 2
Lithuanian (2) 2
Bosnian (1) 1
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 9, pp. 1080 - 1088
Highlights • PTCL has a poor prognosis; existing therapies are insufficient. • We summarize current evidence on novel therapies for relapsed/refractory PTCL. •... 
Hematology, Oncology and Palliative Medicine | Antifolate | Nucleoside analog | Histone deacetylase inhibitor | Fusion protein | Peripheral T-cell lymphoma | Immunomodulatory agent | Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Folic Acid Antagonists - therapeutic use | Stem Cell Transplantation | Topoisomerase Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Diphtheria Toxin - therapeutic use | Topoisomerase Inhibitors - therapeutic use | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Depsipeptides - therapeutic use | Prednisolone - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Alemtuzumab | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Vincristine - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Lymphoma, T-Cell, Peripheral - therapy | Thalidomide - therapeutic use | Folic Acid Antagonists - pharmacology | Care and treatment | Lymphomas | T cells | Health aspects | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 07/2017, Volume 35, Issue 20, pp. 2260 - 2267
Journal Article
Paediatric drugs, ISSN 1174-5878, 2010, Volume 12, Issue 2, pp. 85 - 98
Hodgkin lymphoma is one of the few cancers that affect both adults and children. Cure rates for Hodgkin lymphoma remain among the best for pediatric cancers.... 
Anthracyclines, therapeutic use | Chlormethine, therapeutic use | Alkylating-agents, therapeutic use | Brentuximab-vedotin, therapeutic use | Cisplatin, therapeutic use | Bortezomib, therapeutic use | Bleomycin, therapeutic use | Children | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 07/2011, Volume 365, Issue 3, pp. 203 - 212
BEACOPP combination chemotherapy was compared with ABVD chemotherapy in advanced Hodgkin's disease. BEACOPP therapy was associated with higher initial rates of... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease | Index Medicus | Abridged Index Medicus
Journal Article
British journal of haematology, ISSN 0007-1048, 06/2015, Volume 169, Issue 5, pp. 672 - 682
Summary This multicentre, randomized, phase II study was conducted to examine whether the addition of mogamulizumab, a humanized anti‐CC chemokine receptor 4... 
mogamulizumab | randomized phase II study | CCR4 | adult T‐cell leukaemia‐lymphoma | antibody therapy | Adult T-cell leukaemia-lymphoma | Mogamulizumab | Antibody therapy | Randomized phase II study | Life Sciences & Biomedicine | Hematology | Science & Technology | Doxorubicin - therapeutic use | Nitrosourea Compounds - adverse effects | Prednisolone - adverse effects | Nitrosourea Compounds - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Carboplatin - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Leukemia-Lymphoma, Adult T-Cell - drug therapy | Carboplatin - therapeutic use | Vindesine - adverse effects | Vindesine - therapeutic use | Aged, 80 and over | Adult | Female | Prednisolone - therapeutic use | Etoposide - adverse effects | Leukemia-Lymphoma, Adult T-Cell - mortality | Etoposide - therapeutic use | Treatment Outcome | Leukemia-Lymphoma, Adult T-Cell - pathology | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Doxorubicin - adverse effects | Chemotherapy | Lymphomas | T cells | Leukemia | Cancer | Index Medicus | Haematological Malignancy | Research Paper
Journal Article
The Lancet (British edition), ISSN 0140-6736, 05/2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear. We... 
Internal Medicine | Radiotherapy Dosage | Doxorubicin/adverse effects | Etoposide/adverse effects | Procarbazine/adverse effects | Prospective Studies | Hodgkin Disease/drug therapy | Humans | Middle Aged | Proportional Hazards Models | Male | Treatment Outcome | Positron-Emission Tomography | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Prednisone/adverse effects | Treatment Failure | Adolescent | Survival Analysis | Adult | Female | Cyclophosphamide/adverse effects | Vincristine/adverse effects | Neoplasm Staging | Bleomycin/adverse effects | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Doxorubicin - therapeutic use | Hodgkin Disease - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Hodgkin Disease - drug therapy | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - therapeutic use | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article